SCHEMBL434944

SCHEMBL434944

NOP(N)(=O)ON

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL434945 0.70
SCHEMBL165076 0.67
SCHEMBL37063 0.64
SCHEMBL29116848 0.64
SCHEMBL2857559 0.64
SCHEMBL8615162 0.64 FDPS (0.50)
SCHEMBL8399407 0.62 CTSA (0.50)
SCHEMBL17004026 0.61
SCHEMBL50123 0.61
SCHEMBL25318739 0.61

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073678-A2 PHOSPHOLIPIDS CONTAINING A HETEROCYCLE RING HAVING A TERTIARY AMINE OR AMIDE OMEGA THERAPEUTICS, INC. (US) 2024-04-04 WO claimed
EP-4314297-A1 TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE Specific Biologics Inc. (CA) 2024-02-07 EP claimed
EP-4301859-A1 ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES Code Biotherapeutics, Inc. (US) 2024-01-10 EP claimed
WO-2022200858-A1 TARGETING ONCOGENTIC MUTATIONS WITH DUAL-CLEAVING ENDONUCLEASE SPECIFIC BIOLOGICS INC. (CA) 2022-09-29 WO claimed
WO-2022187586-A1 ENHANCED TARGETING USING ANTIBODY-OLIGONUCLEOTIDE CONJUGATES CODE BIOTHERAPEUTICS, INC. (US) 2022-09-09 WO claimed
WO-2017106767-A1 PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM THE SCRIPPS RESEARCH INSTITUTE (US) 2017-06-22 WO claimed
CN-103998454-A Double-stranded oligonucleotide compounds for the treatment of hearing and balance disorders QUARK PHARMACEUTICALS INC 2014-08-20 CN claimed
EP-1765844-B1 PURINE NUCLEOTIDE DERIVATIVES SOLVELL AS (NO) 2014-07-30 EP claimed
CN-103221055-A Modulation of TIMP1 and TIMP2 expression NITTO DENKO CORP 2013-07-24 CN claimed
US-8153609-B2 Purine nucleotide derivatives LAURAS AS (NO) 2012-04-10 US claimed
EP-1611249-A4 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS INC (US) 2006-06-28 EP claimed
EP-1611249-A1 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS, INC. (US) 2006-01-04 EP claimed
WO-2004097049-A1 OLIGORIBONUCLEOTIDES AND RIBONUCLEASES FOR CLEAVING RNA ISIS PHARMACEUTICALS, INC. (US) 2004-11-11 WO claimed
WO-2026107101-A2 COMPOUNDS FOR TARGETING FERREDOXIN 2 (FDX2) IN FRIEDREICH ATAXIA (FRDA) THE GENERAL HOSPITAL CORPORATION (US) 2026-05-21 WO disclosed
WO-2026059707-A9 METHODS FOR CONJUGATING SEQUENCES OF INTEREST TO BEADS IN A SINGLE BULK REACTION BECTON, DICKINSON AND COMPANY (US) 2026-05-15 WO disclosed
WO-2026090025-A1 VARIANT RNA-GUIDED CAS12F4 NUCLEASES FOR SINGLE-STRAND CLEAVAGE INARI AGRICULTURE TECHNOLOGY, INC. (US) 2026-04-30 WO disclosed
EP-0570575-A1 BICYCLOAZAMACROCYCLOPHOSPHONIC ACID, CONJUGATES, CONTRAST AGENTS AND PREPARATION THE DOW CHEMICAL COMPANY (US) 1993-11-24 EP disclosed
WO-1993011802-A1 BICYCLOAZAMACROCYCLOPHOSPHONIC ACID, CONJUGATES, CONTRAST AGENTS AND PREPARATION THE DOW CHEMICAL COMPANY (US) 1993-06-24 WO disclosed
WO-1993011801-A1 BICYCLOPOLYAZAMACROCYCLOPHOSPHONIC ACID COMPLEXES, THEIR PREPARATION, CONJUGATES AND RADIOPHARMACEUTICALS THE DOW CHEMICAL COMPANY (US) 1993-06-24 WO disclosed
EP-0296854-A2 Method for processing light-sensitive silver halide color photographic material KONICA CORPORATION (JP) 1988-12-28 EP disclosed